Concepedia

Author

Nianmin Shi

Beijing Center for Disease Prevention and Control

Also Known As

Nian-Min Shi, NianMin Shi, Nianmin Shi

15

Publications

556

Citations

8

H-Index

7

Concepts

All Affiliations

Beijing Center for Disease Prevention and ControlNational Institutes for Food and Drug ControlBeijing Chaoyang Emergency Medical CenterJiangsu Provincial Center for Disease Control and Prevention
NS

About

Nianmin Shi is an author at Beijing Center for Disease Prevention and Control specializing in vaccine safety, vaccination, and vaccine development.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

382

2

Immunology

1

1

382

3

Vaccine Development

1

1

382

4

Infection Control

1

1

382

5

Vaccination

1

1

382

Nianmin Shi

×

6

Publications

516

Citations

6

H-Index

YearCitations

Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Fengcai Zhu, Fanyue Meng, Jingxin Li,

The Lancet

2013

382

2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study

Mingwei Wei, Fanyue Meng, Shiyuan Wang,

The Journal of Infectious Diseases

2016

65

Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects

Nianmin Shi, Yibin Zhang, Huizhen Zheng,

Human Vaccines & Immunotherapeutics

2017

31

Analysis of risk factors for persistent infection of asymptomatic women with high-risk human papilloma virus

Nianmin Shi, Qiang Lu, Li Li,

Human Vaccines & Immunotherapeutics

2017

16

Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above

Jing Wang, Fengji Luo, Zijian Feng,

Human Vaccines & Immunotherapeutics

2017

12

Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase Ⅱb randomized, double-blind, parallel-controlled study

Li Li, Yufeng Li, Yunhua Bai,

Vaccine

2022

10

Page 1